Munekazu Kanemitsu Selected Research

septide

10/2022

Therapeutic effect of targeting Substance P on the progression of osteoarthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Munekazu Kanemitsu Research Topics

Disease

4	Osteoarthritis 10/2022 - 09/2020
3	Pain (Aches) 10/2022 - 01/2021
3	Knee Osteoarthritis 10/2021 - 01/2021
2	Sclerosis 10/2022 - 09/2020
2	Wounds and Injuries (Trauma) 07/2019 - 01/2018
1	Osteophyte 05/2022
1	Cysts 05/2022
1	Rheumatoid Arthritis 01/2021
1	Congenital Abnormalities (Deformity) 01/2021
1	Akinetic Mutism (Coma Vigil) 01/2012
1	Progressive Multifocal Leukoencephalopathy 01/2012

Drug/Important Bio-Agent (IBA)

2	MMEIBA 10/2021 - 01/2021
1	septideIBA 10/2022
1	Therapeutic UsesIBA 10/2022
1	Substance PIBA 10/2022
1	GelsIBA 01/2021
1	atelocollagenIBA 01/2021
1	Fibrin Tissue Adhesive (Fibrin Sealant)IBA 01/2021
1	Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)IBA 09/2020
1	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 09/2020
1	Mefloquine (Lariam)FDA LinkGeneric 01/2012

Therapy/Procedure

2	Arthrodesis 01/2021 - 07/2019
1	Bone Plates (Bone Plate) 05/2022
1	Drug Therapy (Chemotherapy) 01/2021
1	Minimally Invasive Surgical Procedures 07/2019
1	Traction 01/2018
1	Therapeutics 01/2012